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ABSTRACT
Aggressive lethal prostate cancer is characterised by tumour invasion, metastasis 
and androgen resistance. Understanding the mechanisms by which localised disease 
progresses to advanced lethal stages is key to the development of effective therapies. 
Here we have identified a novel role for the transcription factor, SOX9, as a driver 
of aggressive invasive prostate cancer. Using genetically modified mouse models, 
we show that increased Sox9 expression in the prostate epithelia of animals with 
Pten loss leads to a highly invasive phenotype and metastasis. In depth analysis 
of these mice and related in vitro models reveals that SOX9 acts a key regulator of 
various processes that together promote tumour progression. We show that this 
factor promotes cell lineage plasticity with cells acquiring properties of basal stem 
cells and an increase in proliferation. In addition, increased SOX9 leads to changes 
in cytoskeleton and adhesion, deposition of extracellular matrix and epithelia to 
mesenchyme transition, properties of highly invasive cells. Analysis of castrated mice 
showed that the invasive phenotype driven by SOX9 is independent of androgen 
levels. Our study has identified a novel driver of prostate cancer progression and 
highlighted the cellular and molecular processes that are regulated by Sox9 to achieve 
invasive disease.
INTRODUCTION
Prostate cancer is a leading cause of cancer mortality 
in men in the western world. Lethal aggressive disease 
is characterised by tumour invasion, metastasis and 
castration resistance [1]. Identifying and understanding 
the processes that drive prostate cancer progression is an 
important challenge. The PTEN (phosphatase and tensin 
homolog deleted on chromosome 10) tumour suppressor 
gene has been implicated in prostate cancer with late-
stage disease showing loss of function in over 60% of 
samples [2, 3]. Mice lacking Pten in the prostate show 
prostate intraepithelial neoplasia (PIN) that progresses to 
adenocarcinoma in older animals with minimal invasive 
properties [4]. These animals have been used to identify 
factors that cooperate with Pten loss to drive prostate 
cancer progression to more aggressive stages [5, 6].
The transcription factor SOX9 has been shown to be 
a key regulator in various processes during embryogenesis, 
stem cell commitment and cancer. In the prostate, we and 
others have shown that it is expressed at early stages of 
organogenesis and required for prostate development [7, 
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8]. SOX9 has been implicated in prostate cancer, with 
high levels of SOX9 found in early stages of prostate 
neoplasia and high grade PIN in mice and associated 
with increasing Gleason grade in humans [9]. Proposed 
oncogenic mechanisms to achieve increased SOX9 include 
transcriptional activation by ERG [10], which is highly 
expressed in tumours with TMPRSS2:ERG fusions, and 
loss of Zbtb7a, encoding a protein that antagonizes SOX9 
activity [11]. in vivo functional studies have shown that 
overexpression of Sox9 in prostate epithelia in transgenic 
mice induced increased proliferation and high grade 
PIN in mice that also had a heterozygous Pten deletion 
[9]. Moreover, Sox9 loss inhibited tumour formation in 
two prostate cancer mouse models (TRAMP and Myc 
overexpression)[7].
Here we identify a novel role for SOX9 at later 
stages of prostate cancer progression. Analyses of 
genetically modified mice show that overexpression of 
Sox9 in the prostate of mice with a homozygous Pten 
deletion leads to highly invasive prostate cancer and 
metastasis. Our studies reveal that Sox9 regulates various 
processes that together drive increased proliferation and 
concerted stromal cell invasion and metastasis, hallmarks 
of aggressive disease.
RESULTS
SOX9 promotes highly invasive tumour 
formation in Pten deficient prostates
In an effort to determine the role of SOX9 in 
aggressive prostate cancer we generated genetically 
modified mice that express extra levels of Sox9 in prostate 
epithelia in addition to a homozygous Pten deletion. 
For this, mice containing a construct where Sox9 is 
conditionally expressed under the control of a ubiquitous 
promoter in tissues where Cre is expressed (Z/Sox9, 
[9]) were bred with mice with a homozygous Pten loxP 
containing allele (Ptenfl/fl, [12]) and a transgene where Cre 
is driven by a Probasin derived promoter (PbCre4 [13]) 
(the Z/Sox9tg/+; Ptenfl/fl; PbCretg/+ mice are referred to as 
Sox9;Pten;PBCre mutants throughout the manuscript). 
This Sox9 containing transgene also drives expression 
of GFP, allowing us to specifically follow prostate 
epithelial cells that overexpress Sox9. As expected, 
Sox9;Pten;PBCre mutant prostates were positive for GFP 
staining (Figure 1A). Initial analysis of prostates from 3 
month old mice showed that Sox9;Pten;PBCre mutants 
had a larger size compared to Pten;PBCre mutants (Figure 
1A and 1B). Sections of these prostates revealed prostatic 
ducts filled with cells and high grade PIN, as seen in 
Pten;PBCre mutant animals. In contrast to Pten;PBCre 
mutant animals, Sox9;Pten;PBCre prostates had abundant 
evidence of a highly invasive phenotype that was focal 
in nature and associated with an increase in stromal 
tissue (Figure 1C). The epithelial cells invading into the 
surrounding stroma expressed high levels of SOX9 (Figure 
1D). As Sox9 is expressed in normal prostate, we used 
GFP staining to reveal transgenic Sox9 expression. This 
analysis confirmed that GFP positive cells show elevated 
levels of SOX9 and that the invading epithelial cells 
express transgenic Sox9 (Figure 1E and Supplementary 
Figure 1 [9]). Consistent with the invasive phenotype we 
observe metastatic GFP positive cells in lymph nodes and 
lungs of 6 month old Sox9;Pten;PBCre mutants, a process 
that we do not observe in Pten;PBCre mutant animals at 
this stage (Supplementary Figure 2).
Increased proliferation in Sox9;Pten;PBCre 
mutant prostates
The larger size of Sox9;Pten;PBCre mutant 
prostates prompted us to look at proliferation in this 
tissue. To determine the specific effect of transgenic 
Sox9 we stained prostate sections with Ki67, a marker of 
proliferation, and GFP antibodies. These studies showed 
that Sox9;Pten;PBCre mutant prostates have a significant 
increase in Ki67 positive epithelial cells that were also 
positive for GFP, compared to GFP negative cells or to 
Pten;PBCre mutant animals (Figure 2A and 2B). To 
understand the mechanisms relating to proliferation 
regulated by Sox9, we stained Sox9;Pten;PBCre mutant 
prostates with several markers and observed an increase 
in the expression of Cyclin D1, particularly in invasive 
regions (Figure 2C). Pten;PBCre mutant prostates have 
been reported to show senescence that is bypassed 
when other oncogenic insults such as Tp53 or Zbtb7a 
loss are present [11, 14]. Due to the focal nature of the 
phenotype, we used antibody staining to investigate 
senescence associated genes and found no major 
difference in expression of p53, p27, p16 and p19 between 
Sox9;Pten;PBCre and Pten;PBCre mutant prostates 
(Figure 2C). Based on the study of mice with Zbtb7a 
and Pten loss, which show a decrease in PTEN induced 
senescence (PIS) and an increase in SOX9 transcriptional 
activity [11], we investigated the expression of the 
tumours suppressor retinoblastoma (RB). This analysis 
showed decreased RB expression in Sox9;Pten;PBCre 
mutant prostates compared to Pten;PBCre mutants (Figure 
2C). In support of this, direct evidence that RB loss can 
overcome PIS has been shown in prostates that have both 
Rb and Pten deleted [15].
Adhesion phenotype in Sox9;Pten;PBCre mutant 
prostates
Further analysis of the invasive phenotype in 
Sox9;Pten;PBCre mutant prostates showed that it is focal 
and found in all prostatic lobes although a lower incidence 
is seen in the ventral prostate, possibly due to variation in 
the expression of Cre in different lobes (Figure 3A and 3B, 
[13]). It is characterised by the disruption of the stromal 
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barrier, as shown by the interrupted smooth-muscle (SMA) 
actin staining pattern surrounding the duct (Figure 3C). 
An increase in stromal tissue is observed in the invasive 
regions as well as high levels of extra cellular matrix 
markers such as fibronectin and collagen when compared 
to Pten;PBCre mutant animals (Figure 2C). These studies 
indicated that high levels of Sox9 lead to a change in 
adhesive properties. To investigate this hypothesis we 
overexpressed SOX9 in LNCaP cells, which do not 
express PTEN. LNCaP cells with high levels of SOX9 
showed a difference in cellular morphology with a flatter 
appearance than control cells (Figure 3D). This difference 
was highlighted with Phalloidin staining, which showed 
an increase in F-actin in SOX9 expressing cells (Figure 
Figure 1: High levels of Sox9 drive Pten loss neoplasia to highly invasive prostate cancer. (A) Bright-field and GFP whole-
mount mount images of prostates with Pten deletion (Pten;PBCre) or Pten deletion and Sox9 overexpression (Pten;Sox9;PBCre). The 
dorsal-lateral-ventral lobes (DLVP) and anterior lobes (AP) from individual animals of each genotype are shown. (B) Wet weights of 
prostates with Pten deletion or Pten deletion and Sox9 overexpression, * is p<0.05. (C) Haematoxylin and eosin (H&E) staining of sections 
of AP and dorsal-lateral lobes (DLP) of prostates with Pten deletion or Pten deletion and Sox9 overexpression. Arrowheads indicate 
epithelial cells invading the stroma. (D) Sox9 staining and (E) GFP staining of sections of prostates with Pten deletion or Pten deletion and 
Sox9 overexpression.
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Figure 2: High levels of Sox9 promote proliferation of Pten deficient prostate cells. (A) Ki67 staining of sections of prostates 
with Pten deletion or Pten deletion and Sox9 overexpression. (B) Ki67 and GFP immunofluorescence staining of sections of prostates with 
Pten deletion or Pten deletion and Sox9 overexpression. White arrowheads indicate Ki67 positive cells. Bar chart showing quantification of 
Ki67 positive cells in prostates with Pten deletion or Pten deletion and Sox9 overexpression, * is p<0.05. For double mutant prostates, Ki67 
positive cells were quantified from cells that overexpressed Sox9 (GFP+) and cells that did not (GFP-). (C) Cyclin D1, p53, p27, p16, p19 
and RB staining of sections of prostates with Pten deletion or Pten deletion and Sox9 overexpression.
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Figure 3: Sox9 promotes epithelial invasion, F-actin remodelling and adhesion to Fibronectin. (A) GFP immunofluorescence 
staining of a section of a prostate with Pten deletion and Sox9 overexpression showing focal invasion of GFP positive cells. (B) Bar chart 
showing quantification of tumours with epithelial invasion in prostates with Pten deletion or Pten deletion and Sox9 overexpression. AP is 
anterior lobes, DLP is dorsal-lateral lobes and VP is ventral lobes. (C) Smooth-muscle actin (SMA), Masson’s Trichrome, and Fibronectin 
staining of sections of Pten prostates, prostates with Pten deletion or prostates with Pten deletion and Sox9 overexpression. Arrows mark 
areas that have lost SMA. (D) Bright-field images and Phalloidin staining with DAPI counterstain of LNCaP cells expressing GFP or Sox9. 
(E) Quantitative RT-PCR of GSN, MACF1 and PALLD in LNCaP cells expressing RFP or Sox9. (F) Images of DAPI stained LNCaP cells 
expressing RFP or Sox9 adhered to Fibronectin. Bar chart of the number of LNCaP cells expressing RFP, GFP or Sox9 adhered to Collagen 
I or Fibronectin. ** is p<0.01.
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3D). Consistent with an effect of Sox9 on adhesion, genes 
associated with adhesomes, GSN, MACF1 and PALLD, 
were found to be increased in cells expressing high levels 
of SOX9 (Figure 3E). Moreover, these cells showed 
increase adhesion to fibronectin but not to collagen (Figure 
3F).
Epithelia to mesenchyme transition in 
Sox9;Pten;PBCre mutant prostates
The highly invasive phenotype observed in 
Sox9;Pten;PBCre mutant prostates suggested an increase 
in epithelia to mesenchyme transition (EMT), which has 
been associated with SOX9 activity in other tissues. To 
address this possibility sections from Sox9;Pten;PBCre 
mutant prostates were stained with antibodies to 
E-cadherin or Vimentin together with GFP, to mark 
the cells expressing transgenic Sox9. Cells undergoing 
EMT have been shown to downregulate the expression 
of the epithelial marker E-cadherin and upregulate the 
mesenchymal marker vimentin. Our studies show that 
some GFP positive cells do show this phenotype and are 
particularly abundant in regions of high invasion (Figure 
4A and 4B). Several key regulators of EMT have been 
shown to promote the loss of epithelial characteristics and 
the gain of mesenchymal traits [16]. Analysis of several 
of these regulators showed that there is an increase in 
SLUG (encoded by Snai2) and ZEB1 positive cells 
in Sox9;Pten;PBCre mutant prostates (Figure 4C). To 
investigate whether EMT is a direct effect of increased 
Sox9 in prostate cells, we analysed this process in LNCaP 
cells that had high levels of SOX9. These cells had an 
increase in Vimentin positive cells when compared to 
control cells, however, E-cadherin was not found to be 
reduced (Figure 4D, 4E and 4F). Analysis of the expression 
of EMT regulators revealed an increase in ZEB1 but not 
SNAIL, SLUG or TWIST in LNCaP cells with high SOX9 
(Figure 4G) suggesting SOX9 can promote mesenchymal 
features in prostate cells, possibly through ZEB1.
Cell fate identity of invasive cells in 
Sox9;Pten;PBCre mutant prostates
Prostate epithelial ducts are formed of basal and 
luminal cells. We therefore used antibody staining to 
investigate the cell fate identity of the invasive cells in 
Sox9;Pten;PBCre mutant prostates. Our studies revealed 
that invasive cells within the stroma express both luminal 
(CK8) and basal (CK5 and p63) markers (Figure 5A). 
Co-staining of Sox9;Pten;PBCre mutant prostates with 
GFP showed that some invasive regions had a high 
number of basal cells that coexpressed transgenic Sox9 
while others regions lacked basal cells (Figure 5B). 
The prostate basal cell population has been proposed to 
contain a high number of progenitor/stem cells [17, 18]. 
The relative increase in basal markers in Sox9;Pten;PBCre 
mutant prostates and the association of SOX9 with stem 
cell activity in other tissues, prompted us to look at stem 
cell markers. Antibody staining revealed an increase 
in BMI1, SOX2 and TCF4 in neoplastic regions of 
Sox9;Pten;PBCre prostates, including the invasive 
regions, relative to Pten;PBCre mutants (Figure 5C). This 
result was confirmed in LNCaP cells expressing high 
levels of Sox9 that showed an increase in BMI1, SOX2 
and TCF4 proteins (Supplementary Figure 3), although we 
could not detect p63 in these cells.
Effect of castration on Sox9;Pten;PBCre mutant 
prostates
Castration is the first line of therapy for prostate 
cancer patients in the clinic and SOX9 has been 
proposed to interact with AR [19]. Therefore we wanted 
to investigate whether the phenotype observed in 
Sox9;Pten;PBCre mutants was dependent on AR levels. 
Analysis of castrated mice showed that Sox9;Pten;PBCre 
mutant prostates were similar in size to Pten;PBCre 
mutant prostates, which were both smaller than their 
intact counterparts. However, the invasive phenotype 
was still observed in the Sox9;Pten;PBCre mutant 
prostate highlighted by the lack of stromal SMA staining 
surrounding the ducts (Figure 6A and 6B). Consistent 
with the lack of size difference, the levels of castration 
resistant proliferation, as measured by Ki67 staining, and 
apoptosis, as measured by Caspase 3 staining, were found 
to be similar between Sox9;Pten;PBCre and Pten;PBCre 
mutants (Figure 6B and 6C). Levels of nuclear AR 
staining were low in both mutants, a phenotype that was 
found in Sox9;Pten;PBCre mutant prostates that had not 
been castrated (Figure 6B and Supplementary Figure 4).
DISCUSSION
SOX9 has been implicated in cancer in many tissues 
and its role has been shown to be varied and context 
dependent. We have been investigating the function of this 
factor in the normal and neoplastic prostate. Our previous 
work had shown that Sox9 can promote tumour initiation 
in mice with a heterozygous Pten mutation. This study 
identifies a novel role for SOX9 as a driver of aggressive 
late stage invasive prostate cancer in homozygous Pten 
mutant animals. In addition, we show that its mechanism 
of action is to regulate several key processes that together 
promote highly invasive disease. Our study reveals that 
high Sox9 levels lead to Pten mutant prostate epithelial 
cells increasing proliferation and acquiring properties of 
basal stem cells; to the induction of EMT, the deposition 
of extracellular matrix and changes in cytoskeleton and 
adhesion, properties that promote a highly invasive 
phenotype. Our analysis is consistent with SOX9 being 
a key regulator of these processes rather than regulating 
one event that brings about these phenotypes. A similar 
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Figure 4: Sox9 promotes Epithelial to Mesenchymal Transition in Pten mutant prostate cells. (A) E-Cadherin and GFP 
immunofluorescence staining of sections of prostates with Pten deletion and Sox9 overexpression. White arrows mark invading cells that 
have reduced E-Cadherin expression. (B) Vimentin and GFP immunofluorescence staining of sections of prostates with Pten deletion and 
Sox9 overexpression. White arrowheads mark invading cells that express Vimentin and GFP. (C) Slug and ZEB1 staining of sections of 
Pten prostates, prostates with Pten deletion or prostates with Pten deletion and Sox9 overexpression. Arrows highlight cells with positive 
staining. (D) Vimentin staining with DAPI counterstain of LNCaP cells expressing GFP or Sox9. Insert shows higher magnification. (E) 
Western bot of LNCaP cells expressing RFP or SOX9 with antibodies against E-Cadherin, Vimentin and GAPDH. Quantitative RT-PCR of 
LNCaP cells expressing RFP or Sox9 for (F) Vimentin and CHD1 (E-Cahderin) and (G) SNAIL, SLUG, TWIST and ZEB1.
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role has recently been proposed for this factor in basal cell 
carcinoma (BCC) [20].
Lineage plasticity has been proposed to be a 
mechanism not only of tumour progression to aggressive 
stages but also resistance to therapy [15, 21]. This change 
in cell fate is thought to occur through the increase in 
cells with stem like properties [22]. Recent transcriptome 
analysis has identified an association between human basal 
cells and aggressive prostate disease [18]. Our studies 
reveal that Sox9 can induce a more basal-like phenotype 
in Pten mutant prostates. In addition, we identified an 
increase in the stem cell markers Sox2, Tcf4 and Bmi1 
in both human and mouse prostate cells overexpressing 
SOX9. Direct regulation of Bmi1 expression by SOX9 
Figure 5: Sox9 promotes an increase in the expression of stem cell markers in Pten mutant prostate cells. (A) CK8, CK5 
and p63 staining of sections of prostates with Pten deletion or Pten deletion and Sox9 overexpression. Arrows mark cells invading the 
stroma. (B) p63 and GFP immunofluorescence staining of sections of prostates with Pten deletion and Sox9 overexpression. White arrows 
mark p63 and GFP double positive cells invading the stroma. White arrowheads mark p63 negative and GFP positive cells invading the 
stroma. White line demarcates the epithelial ducts. (C) BMI1, SOX2 and TCF4 staining of sections of Pten prostates, prostates with Pten 
deletion or prostates with Pten deletion and Sox9 overexpression.
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has been shown in mouse embryonic fibroblasts and 
proposed to occur in colorectal cancer [23]. A more 
indirect mechanism could give rise to the high levels of 
SOX2 in Sox9;Pten;PBCre mutants as loss of RB has been 
proposed to lead to an increase in SOX2 expression, which 
was greatly augmented with concomitant TP53 loss [15].
A striking effect of high levels of SOX9 on LNCaP 
cells is their change in morphology and adhesion 
properties. In a study on BCC, SOX9 has been shown to 
directly regulate genes involved in adhesion, cytoskeleton 
remodelling and extracellular matrix [20]. Consistent 
with this, we observe an increase in genes involved in 
cell shape and adhesion. Our work indicates that through 
the regulation of cytoskeleton dynamics and adhesion, 
SOX9 contributes to Pten mutant cells altering their 
epithelial properties and becoming more motile. The actin 
remodelling genes MACF1 and PALLD that we show are 
increased in SOX9 overexpressing cells have been shown 
to promote cell migration [24, 25]. Antibody staining on 
Sox9;Pten;PBCre mutant prostates revealed groups of 
invasive cells, suggesting a mechanism of collective cell 
migration. Presumably this process was further influenced 
by the ECM changes in the stroma.
SOX9 has been associated with the process of EMT 
in many tissues including embryonic neural crest [26]. 
Evidence of this process was found in Sox9;Pten;PBCre 
mutant prostates with a subset of GFP positive cells 
showing Vimentin staining. Increased staining was also 
observed in LNCaP cells expressing increased SOX9, 
although not in all cells. Moreover, an increase in ZEB1, 
an EMT regulator, was observed in both models. EMT is 
thought to be a transient process, therefore the sporadic 
staining we observed could reflect cells at different stages 
of the pathway.
Consistent with the highly invasive phenotype 
observed in Sox9;Pten;PBCre mutant prostates, we did 
find evidence of metastasis in tissues such as lymph nodes 
and lungs. However, in most cases these are single or 
small cell clusters suggesting that high levels of SOX9 
promote cell migration to secondary sites but other factors 
are required to establish colonisation and growth at these 
locations. A similar effect was observed in a breast cancer 
study where overexpression of Sox9 led to micrometastasis 
in the lung but macrometastases were only observed when 
cells had increased levels of Slug [27].
Our results show directly that increased levels 
of SOX9 are required to drive both tumour initiation 
and invasive advanced disease and that it does this in 
association with other oncogenic pathways such as loss 
of Pten. SOX9 is expressed in the normal prostate and 
mechanisms to achieve increased levels in tumours 
have been proposed. These include regulation of SOX9 
expression by ERG [10], which is found in tumours 
with TMPRSS2:ERG fusions, and loss of Zbtb7a, 
Figure 6: Castration of animals with Pten deletion and high Sox9 does not prevent epithelial invasion into the stroma. 
(A) Haematoxylin and eosin (H&E) staining of sections of prostates with Pten deletion or Pten deletion and Sox9 overexpression from 
3 month old animals castrated at 2 months. (B) GFP, smooth-muscle actin (SMA), Androgen receptor (AR) and Caspase 3 staining of 
sections of prostates with Pten deletion or Pten deletion and Sox9 overexpression from castrated animals. Arrows indicate invading cells. 
Arrowheads indicate Caspase 3 positive cells. (C) Ki67 and GFP staining of sections of prostates with Pten deletion or Pten deletion 
and Sox9 overexpression from castrated animals. DAPI is nuclear counterstain. White arrowheads indicate Ki67 positive cells. Bar chart 
showing quantification of Ki67 positive cells in prostates with Pten deletion or Pten deletion and Sox9 overexpression from castrated 
animals.
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which encodes a factor proposed to antagonize SOX9 
function rather than expression [11]. This dependence 
on levels might explain the focal nature of the phenotype 
in Sox9;Pten;PBCre mutant animals as only some cells 
achieve the required amount of protein to drive aggressive 
disease.
In conclusion, we identified a novel role of SOX9 
as a driver of invasive prostate cancer, a property of 
aggressive disease. Our study shows that SOX9 is a key 
regulator of various cellular and molecular processes that 
together act to drive tumour progression. The genetically 
modified mice in this study are an ideal model to study the 
process of cell invasion and disease progression in prostate 
cancer and identify biomarkers of this process.
MATERIALS AND METHODS
Mouse strains
The PBCre transgenic mice (ARR2PBCre) have 
been described previously [13]. Mice with the conditional 
allele of Pten were obtained from The Jackson Laboratory 
[28]. The Z/Sox9 transgenic mice were kindly provided 
by Kathryn Cheah [9]. These male animals were bred 
on a mixed genetic background. All mouse work was 
carried out in accordance with the Institute of Cancer 
Research guidelines and with the UK Animals (Scientific 
Procedures) Act 1986.
Mouse prostate histology
Histological phenotype of samples was assessed on 
haematoxylin and eosin stained sections. Serial sections 
were then stained for immunohistochemical analysis. 
Histological assessment was based on published guidelines 
and assisted by a pathologist [29]. An unpaired t-test 
was performed to test if there is a significant difference 
between the wet weight of prostate tumours.
Quantification of cell proliferation
Proliferation was quantified by immunofluorescent 
stain of sections with an antibody against Ki67. The 
number of proliferating cells was calculated by counting 
the number of nuclear Ki67 stained cells with and shown 
as a percentage of the total number of cells stained with 
nuclear DAPI. Sox9;Pten mutant tumours were also 
stained with an antibody against GFP, and the number of 
Ki67 single positive cells and Ki67/GFP double positive 
cells were counted. Cells from at least 4 high power fields 
were counted per animal, which totalled more than 900 
cells per animal. Three animals of each genotype were 
analysed. Randomly selected fields were counted for 
control analysis. An ANOVA or t-test was used to test 
if there was a significance difference in the number of 
proliferating cells between each group.
Immunohistochemistry, immunofluorescence 
and western blotting
Mouse tissues were fixed overnight in 4% 
paraformaldehyde (PFA), dehydrated in an ethanol 
gradient series, washed in Histoclear and embedded in 
wax. Antigen retrieval was obtained by boiling sections 
in citrate buffer (0.1 M sodium citrate pH6 and 0.05% 
Tween) and sections were treated with 3% H2O2 to block 
endogenous peroxidase activity. Sections were blocked 
in 10% sheep serum and then incubated with primary 
antibodies in 1% sheep serum overnight. For DAB 
chromogen (Agilent) staining the ABC vector kit (Vector 
Laboratories) was used with biotinlyated secondary 
antibodies according to manufacturer's instructions and 
were counterstained with haematoxylin. Masson’s stain 
was performed using the Trichrome light green stain from 
TCS Biosciences (HS773-LG). For all mouse tumour 
stains, sections were processed from at least three animals 
of each genotype. For immunofluorescence cell staining, 
LNCaP cells were plated on coverslips, fixed for 20 
minutes in 4% PFA and washed in PBS containing 0.01% 
Triton. Cells were then blocked in 10% sheep serum and 
incubated with primary antibodies in 1% sheep serum 
overnight. DAPI was used as a nuclear counterstain. 
TRITC labelled phalloidin (Thermo Fisher Scientific) was 
used to stain F-actin. Secondary fluorescent antibodies 
were obtained from Molecular Probes and were used at 
a 1:1000 dilution. Fluorescent images were visualized 
and collected on a Leica TCS-SP2 confocal microscope. 
Western blotting was performed using standard protocols, 
with cells lysed in RIPA buffer. The following antibodies 
were used; SOX9 (Millipore AB5535), GFP (Abcam 
ab13970), Ki67 (clone SP6, Abcam ab16667), Cyclin D1 
(clone A-12, Santa Cruz sc-8396), p53 (Leica NCL-p53-
CM5), p27 (Dako M7203), p16 (Leica NCL-p16-432), p19 
(Abcam ab80), RB (clone EPR17512, Abcam ab181616), 
Smooth-muscle Actin (clone 1A4, Sigma A2547), 
Fibronectin (Agilent A0245), E-Cadherin (clone 36, BD 
Biosciences 610181), Vimentin (clone EPR3776, Abcam 
ab92547), ZEB1 (clone 3G6, Abcam ab180905), Slug 
(clone C19G7, Cell Signaling Technology 9585), CK8 
(Covance MMS-162P), CK5 (Covance PRB-160P), p63 
(clone 4A4, Santa Cruz sc-8431), BMI1 (clone D20B7, 
Cell Signaling Technology 6964), TCF-4 (clone 6H5-3, 
Millipore 05-511), SOX2 (Abcam ab97959), AR (clone 
PG-21, Millipore 06-680), pAKT (Ser473) (Cell Signaling 
Technology 9271), GAPDH (Abcam ab9485).
Cell line work and lentivirus production and 
infection
LNCaP and 293T cells were STR profiled to 
confirm their identity. Both cell lines were maintained 
in RPMI1640 with 10% FCS and used at low passage 
number (less than 20).
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Sox9 overexpression was achieved by infecting cells 
with Lentiviral particles generated from the construct 
pLenti-GIII-CMV-SOX9-GFP-2A-Puro (LV318630, 
Applied Biological Materials Inc) and control cells 
infected with Lentivirus particles from the plasmid pLenti-
GIII-CMV-RFP-2A-Puro (Applied Biological Materials 
Inc) or GIPZ-GFP (GE Dharmacon). Lentivirus particles 
were made in 293T cells by transfecting the Lentiviral 
plasmid with Lipofectamine 3000 (Thermo Fisher 
Scientific), together with the packaging plasmids psPAX2 
and pMD2.G. Viral supernatants were collected, filtered, 
supplemented with 8 μg/ml polybrene and used to infect 
LNCaP cells.
Cell adhesion assay
96-well plates were coated with 10 μg/ml 
Fibronectin (Sigma, F1141), 10 μg/ml Collagen I (BD 
Biosciences, 354236) or 10 mg/ml heat denatured 
BSA for 2 hours at room temperature and then washed. 
LNCaP cells were dissociating in TrypLE (Thermo Fisher 
Scientific) and seeded at 10,000 cells per well in 100 
μl of media. Cells were incubated at 37°C for 1 hour, 
washed three times with PBS and fixed with 4% PFA 
for 20 minutes at room temperature. To quantify adhered 
cells, cells were stained with DAPI and the total number 
of cells per well were counted using the Celigo Imaging 
Cytometer (Nexcelom) with the Direct Cell Counting 
analysis.
RNA isolation and quantitative RT-PCR
RNA was purified from cells using the RNeasy 
kit (Qiagen) and cDNA was made using SuperScript IV 
reverse transcriptase (Thermo Fisher Scientific), following 
the manufacturer’s instructions. Quantitative RT-PCR 
was carried out using Taqman gene expression assays 
using the following probes; GAPDH Hs03929097_g1, 
CDH1 Hs01013958_m1, VIM Hs00958111_m1, SNAI1 
Hs00195591_m1, SNAI2 Hs00161904_m1, TWIST1 
Hs00361186_m1, MACF1 Hs00201468_m1, GSN 
Hs00609272_m1, PALLD Hs00363101_m1.
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